Percutaneous Ablation of Hepatocellular Carcinoma

2000 ◽  
pp. 23-34
Author(s):  
Tito Livraghi
Keyword(s):  
Hepatocellular Carcinoma ◽  
Percutaneous Ablation

scholarly journals Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence

2005 ◽  
Vol 11 (9) ◽  
pp. 1117-1126 ◽  
Author(s):  
Maurizio Pompili ◽  
Vincenzo Giorgio Mirante ◽  
Gianfranco Rondinara ◽  
Luigi Rainero Fassati ◽  
Fabio Piscaglia ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Tumor Recurrence ◽  
Percutaneous Ablation ◽  
Cirrhotic Patients ◽  
Explant Analysis

scholarly journals Current locoregional therapies and treatment strategies in hepatocellular carcinoma

2020 ◽  
Vol 27 (S3) ◽  
Author(s):  
L. Cardarelli-Leite ◽  
A. Hadjivassiliou ◽  
D. Klass ◽  
J. Chung ◽  
S.G.F. Ho ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Biology ◽  
Treatment Strategies ◽  
Current Evidence ◽  
Percutaneous Ablation ◽  
Transarterial Radioembolization ◽  
Combined Use ◽  
Liver Morphology ◽  
Locoregional Therapies ◽  
Bridging To Transplant

Locoregional therapies (LRT) play an important role in the treatment of hepatocellular carcinoma (HCC), with the aim of increasing overall survival while preserving liver function. Different forms of LRT are available and choosing which one is best will depend on technical aspects, liver morphology, tumor biology, and patient’s symptoms. The purpose of this review article is to provide an overview of the current evidence regarding the use of percutaneous ablation, transarterial chemoembolization and transarterial radioembolization for the curative or palliative treatment of HCC. Special situations are also reviewed, including the combined use of systemic therapy with LRT; indications and techniques for bridging to transplant and downstaging; and the use of LRT to treat patients with HCC and macrovascular invasion.

Sequential multidisciplinary treatment of hepatocellular carcinoma: The role of surgery as rescue therapy for failure of percutaneous ablation therapies

2009 ◽  
Vol 100 (7) ◽  
pp. 580-584 ◽  
Author(s):  
Nazario Portolani ◽  
Gian Luca Baiocchi ◽  
Arianna Coniglio ◽  
Luigi Grazioli ◽  
Eleonora Frassi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Rescue Therapy ◽  
Multidisciplinary Treatment ◽  
Percutaneous Ablation

Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice

2015 ◽  
Vol 33 (5) ◽  
pp. 668-674 ◽  
Author(s):  
Giuseppe Cabibbo ◽  
Salvatore Petta ◽  
Marcello Maida ◽  
Calogero Cammà
Keyword(s):  
Hepatocellular Carcinoma ◽  
Randomized Controlled Trials ◽  
Growth Factor Receptor ◽  
Standard Of Care ◽  
Tumor Stage ◽  
Percutaneous Ablation ◽  
Controlled Trials ◽  
Solid Malignancy ◽  
Raf Kinase ◽  
Randomized Controlled

Hepatocellular carcinoma is a challenging malignancy of global importance. It is the sixth most common solid malignancy and the third leading cause of cancer-related death, worldwide. Curative treatments at early stages include liver transplantation, resection and percutaneous ablation, while transarterial chemoembolization can improve survival in patients with intermediate tumor stage. Patients with mild, related symptoms and/or macrovascular invasion or extrahepatic spread are classified under the advanced stage. The standard of care in this group is sorafenib, an inhibitor of Raf kinase and vascular endothelial growth factor receptor, whose effectiveness has been proven by 2 recent randomized controlled trials (RCTs). The aim of this brief review is to highlight the main concerns and pitfalls and to analyze the recent data of literature regarding the efficacy and the management of sorafenib therapy from RCTs to real practice.

Sign in / Sign up

Export Citation Format

Share Document